Automated Bedside Monitoring for Critical Care

Bedside blood monitoring platform used in intensive care units

Provides clinicians with valuable trending data to support early detection of changes

OptiScan Biomedical’s lead product, the OptiScanner® 5000, is a first-of-its-kind bedside blood monitoring platform that provides plasma-based, automated monitoring of patients’ glucose levels without the need for calibration. OptiScan Biomedical is expanding the OptiScanner platform to include additional metabolic and hemodynamic analytes using the same sample of blood.  Learn more

Designed to Monitor What Matters

Achieving Glucose Control

Critically ill patients frequently suffer from stress-induced hyperglycemia, glycemic variability or hypoglycemia which has been associated with increased morbidity and mortality in both diabetic and non-diabetic patients.

The OptiScanner 5000, which directly measures plasma glucose levels using an integrated blood centrifuge and spectrometer, delivers automated monitoring, no-calibration convenience and insights into trending data with the goal of avoiding dangerous glycemic variations and achieving the right level of glucose control.  Learn More

Platform Expansion

The OptiScanner 6000 will represent the first step of platform expansion, with the goal of providing hospitals and healthcare practitioners with a single source that detects both metabolic and hemodynamic analytes, all from the same sample of blood.

The OptiScanner 6000 will automatically measure and trend glucose, hemoglobin and central venous oxygen saturation levels to supply clinicians with early warning signs for critically ill patients at risk for sepsis, shock or bleeding. Learn More

LATEST NEWS

OptiScan Biomedical Enrolls First Patient in Pivotal U.S. Clinical Study of OptiScanner® 5000

Pivotal Trial to Build on Previous Positive Studies; Aims to Further Demonstrate Paradigm-Shifting Potential of Automated, Bedside Glucose Monitoring System in the ICU — The OptiScanner 5000 is the company’s first-of-its-kind automated, bedside glucose monitoring system that provides physicians with critical information to manage patient glucose levels in the ICU. The pivotal trial, known as […]

OptiScan Biomedical’s Breakthrough Continuous Monitoring Platform for the Intensive Care and Critical Care Units Highlighted in Symposium at 34th Annual ISICEM Conference

Company Introduces Next-Generation OptiScanner 6000; Platform to Add Real-Time Monitoring of Key Hemodynamic Measures in ICU Settings —   BRUSSELS, March 21, 2014  — OptiScan Biomedical Corporation, a developer of innovative continuous monitoring systems for use in intensive care units (ICU)/critical care units (CCU), introduced its next-generation OptiScanner™ product as part of a special symposium […]
CAUTION: In the U.S., the OptiScanner system is an investigational device limited by Federal (U.S.) law to investigational use. This investigational product has not been cleared or approved by the U.S. Food and Drug Administration for marketing in the United States. This investigational product is currently undergoing clinical study to verify its safety and effectiveness.
OptiScan Biomedical has received CE Mark certification for the OptiScanner 5000 system.